what is nuclear medicine and pet?
DESCRIPTION
Complete overview of Nuclear Medicine and PET.TRANSCRIPT
Todd Charge Senior Nuclear Medicine Technologist
Hunter Health Imaging Service
What is Nuclear Medicine?
1
What is Nuclear Medicine
• Branch of medicine that uses unsealed radioactive substances in diagnosis and therapy
• These substances consist of pharmaceuticals labelled with radioisotopes - “radiopharmaceuticals”
• In diagnosis, radioactive substances are administered to patients and the radiation emitted is measured and location recorded
• In therapy, radioisotopes are administered to treat disease
2
Administration of Radioactivity • The routes of administration for radiopharmaceuticals
include:
• Intravenous injection: The radiopharmaceutical is injected into a vein
• Subcutaneous injection: The radiopharmaceutical is injected under the skin.
• Inhalation: Some radiopharmaceuticals and radioisotopes are inhaled by the patient
• Ingestion: Radiopharmaceuticals can be ingested
3
Diagnostic Nuclear Medicine
• In diagnostic nuclear medicine, a radiopharmaceutical is chosen that is known to follow a particular desired metabolic pathway
• After comparing the observed biodistribution with that expected for a healthy person, a diagnosis is made
• Exploits the way that the body handles substances differently when there is disease or pathology present
4
Therapeutic Nuclear Medicine
• Nuclear Medicine therapy agents are usually based on beta-emitting radioisotopes although not always
• Beta particles have a much shorter range in tissue than do gamma rays so the radiation dose associated with therapeutic radiopharmaceuticals is limited to the treatment site
• Exploits the way that the body handles substances differently when there is disease or pathology present
5
Production of Radioactivity
• Radioisotopes for use in nuclear medicine are derived from fission processes in reactors or cyclotrons
• The most commonly used liquid radioisotopes are: technetium-99m
iodine-123 and 131
thallium-201
gallium-67
6
Production of Radioactivity
7
Production of Radioactivity
8
Production of Radiopharmaceuticals
• In larger departments production is done in-house in what is know as a “hot lab”
• For smaller departments specialist outside companies can provide individual patient doses delivered to your department
9
Production of Radiopharmaceuticals
10
Production of Radiopharmaceuticals
11
Imaging
• The radiation emitted from the radionuclide inside the body is detected using a gamma camera
• Gamma-cameras consist of a large sodium-iodide scintillation crystal, coupled with an array of associated electronics
• Resolution of approx. 4 to 6 mm and can capture several hundred thousand gamma-ray 'events' per second
12
Imaging
• The gamma-camera will detect the X and Y position of each gamma-ray event, and these coordinates will be used to build an image
13
Imaging
14
Imaging
• Fundamentally different from radiology, magnetic resonance imaging and ultrasound
• These modalities are capable of producing excellent images of internal structural anatomy
• Nuclear medicine images display details of organ function in terms of the uptake and clearance of radiopharmaceuticals
• Research is directed towards the development of new radiopharmaceuticals that follow unexplored metabolic pathways
15
Imaging
16
Imaging
17
Imaging
18
Radiation Safety
• Fundamental difference in the source of radiation exposure
• In Radiology the source of radiation exposure is the imaging equipment eg x-ray tube, CT
• In Nuclear Medicine the source of exposure is the radiopharmaceutical and after administration, the patient
• A gamma-camera does not produce any radiation
19
Radiation Safety - Patients
• A patient undergoing a nuclear medicine procedure will receive a radiation dose
• Doses are adjusted by weight for children
• Some studies are performed on pregnant women
• Doses calculated to give just enough for imaging
• Estimated that every person in Australia will have at least one Nuclear Medicine procedure in their lifetime
20
Radiation Safety - Patients Study Activity Effective Dose Bone scan 800MBq HDP 4.6mSv Lung scan 200MBq MAA 2.2mSv
Renal scan 200MBq MAG3 1.4mSv Myocardial perfusion scan
300 / 1000MBq of MIBI 10.6mSv
Gallium scan 200MBq of Ga 20.0mSv
CXR 0.04mSv Abdo XRay 1.2mSv Lumbar Spine 2.1mSv CT chest 7.8mSv Barium enema 8.7mSv
21
Radiation Safety - Patients
• Natural background radiation in the Sydney area
• 1.4 – 2.5 mSv/y
22
Radiation Safety - Staff
• Three principles Time Distance Shielding
• Staff still work whilst pregnant, right up to time of choosing. Recommend pelvic shielding
• No infertility to staff
• All staff monitored monthly
23
PET
24
What is PET
• Positron Emission Tomography (PET) is rapidly becoming a major diagnostic imaging modality
• Used predominantly in determining
presence and severity of cancers
neurological conditions
cardiovascular disease
25
What is PET
• PET camera measures the biodistribution of positron emitting radionuclides after injection into the patient
• Positron emitting radionuclides are used for their unique simultaneous emission of back to back gamma rays
26
What is PET
27
What is PET
• Is currently the most effective way to check for cancer recurrences
• Studies demonstrate that PET offers significant advantages over other forms of imaging such as CT or MRI scans in diagnosing disease
28
PET
29
PET Radiopharmaceuticals
• Most widely used is F-18 (Fluorine)
• F-18 is labelled to a glucose analog (DeoxyGlucose)
• Forming FDG
• Follows glucose pathway from plasma into cells
• Unlike glucose, FDG is not metabolised and is trapped in cells allowing imaging
• Half-Life 109mins
• Produced in cyclotron
30
Biodistribution
• Every cell in the body uses glucose
• After IV injection patients rest for 40-50mins to allow organ uptake of FDG and clearance from blood plasma into cells
31
Biodistribution
• Any metabolically active muscles will show increased uptake
• Many malignant tumours accumulate FDG due to glycolysis and cell proliferation rate
• Benign tumours usually uptake less FDG so can be potentially distinguished from malignant tumours
32
Use • Cancers for which PET is considered particularly
effective include Lung Head and Neck Colorectal Oesophageal Lymphoma Melanoma Breast Thyroid Cervical Pancreatic Brain
33
Use
• PET is effective in identifying
whether cancer is present or not
if it has spread
if it is responding to treatment
if a person is cancer free after treatment
34
Use
• Early Detection:
Because PET images biochemical activity, it can accurately characterise a tumour as benign or malignant, thereby avoiding surgical biopsy when the PET scan is negative. Conversely, because a PET scan images the entire body, confirmation of other metastasis can alter treatment plans in certain cases from surgical intervention to chemotherapy.
35
Use
• Staging of Cancer: PET is extremely sensitive in determining the full
extent of disease, especially in lymphoma, malignant melanoma, breast, lung, colon and cervical cancers. Confirmation of metastatic disease allows the physician and patient to more accurately decide how to proceed with the patient's management
36
Use
• Assessing the Effectiveness of Chemotherapy:
The level of tumour metabolism is compared on PET scans taken before and after a chemotherapy cycle. A successful response seen on a PET scan frequently precedes alterations in anatomy and would therefore be an earlier indicator of tumour response than that seen with other diagnostic modalities
37
Use
• Checking for recurrences: PET is currently considered to be the most accurate diagnostic procedure to differentiate tumour recurrences from radiation necrosis or post-surgical changes. Such an approach allows for the development of a more rational treatment plan for the patient.